Company Filing History:
Years Active: 2010
Title: Philip-Arthur Hipskind: Innovator in Glucagon Receptor Antagonists
Introduction
Philip-Arthur Hipskind is a notable inventor based in New Palestine, Indiana. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of glucagon receptor antagonists.
Latest Patents
Hipskind holds a patent for "Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses." This invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which exhibit glucagon receptor antagonist or inverse agonist activity. The patent also outlines methods for preparing these compounds and describes pharmaceutical compositions that can be used to treat diabetic and other glucagon-related metabolic disorders.
Career Highlights
Hipskind is associated with Eli Lilly and Company, a leading pharmaceutical firm known for its innovative research and development in healthcare. His work focuses on creating therapeutic solutions that address critical metabolic disorders.
Collaborations
He has collaborated with notable colleagues, including Mark Donald Chappell and Scott Eugene Conner, contributing to advancements in their shared field of expertise.
Conclusion
Philip-Arthur Hipskind's work in developing glucagon receptor antagonists showcases his commitment to advancing medical science. His innovative contributions continue to impact the treatment of metabolic disorders.